← MADRIGAL PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($26.4m) | ($31.2m) | ($32.8m) | ($83.9m) | ($202.2m) | ($241.8m) | ($295.4m) | ($373.6m) | ($465.9m) | ($288.3m) | — | |
| Depreciation, Depletion and Amortization | $156 | $77k | $96k | $112k | $471k | $405k | $467k | $527k | $1.1m | $1.5m | $1.5m | |
| Amortization of Debt Issuance Costs and Discounts | — | — | — | — | $0 | $0 | $797k | $2.4m | $2.1m | $1.6m | — | |
| Share-based Payment Arrangement, Noncash Expense | $7.9m | $3.3m | $13.5m | $22.8m | $20.7m | $26.9m | $31.6m | $49.7m | $79.9m | $98.1m | $121.4m | |
| Share-based Payment Arrangement, Expense | $7.9m | $3.3m | $13.5m | $22.8m | $20.7m | $26.9m | $31.6m | $49.7m | $79.9m | $98.1m | $121.4m | |
| Other Nonoperating Income (Expense) | — | — | — | — | — | — | — | — | — | ($463k) | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | ($7k) | — | — | — | — | — | — | — | $53.8m | $80.7m | ($113.1m) | |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | — | — | $34.1m | $37.0m | ($41.2m) | |
| Net Cash Provided by (Used in) Operating Activities | ($17.6m) |
($22.3m)
-26.75%
|
($25.5m)
-14.29%
|
($41.6m)
-63.19%
|
($157.6m)
-278.53%
|
($183.9m)
-16.73%
|
($224.9m)
-22.26%
|
($324.2m)
-44.19%
|
($455.6m)
-40.51%
|
($189.6m)
+58.39%
|
($197.7m)
-4.31%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $3k | $125k | $22k | $172k | $334k | $209k | $217k | $1.5m | $1.5m | $467k | ($3.5m) | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | — | — | — | $634.1m | $931.3m | — | — | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | — | — | — | $0 | $0 | $0 | — | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | $26.1m | $48.3m | $234.3m | $650.2m | $489.5m | $389.3m | $350.4m | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | $22.0m | ($22.0m) | ($380.1m) | $30.7m | $159.8m | ($5.1m) | $206.7m | ($502.5m) | ($274.4m) | $32.3m | $47.0m | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | — | $0 | $0 | ($2.8m) | — | |
| Proceeds from Issuance of Common Stock | $6.0m | — | — | — | — | — | — | — | — | — | ($23k) | |
| Net Cash Provided by (Used in) Financing Activities | $14.5m |
$173.8m
+1102.46%
|
$314.3m
+80.85%
|
$235k
-99.93%
|
$5.1m
+2065.11%
|
$171.2m
+3265.51%
|
$313.5m
+83.05%
|
$595.1m
+89.86%
|
$735.1m
+23.52%
|
$256.0m
-65.18%
|
$251.0m
-1.93%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | — | — | — | — | ($231.6m) | $5.1m | $98.8m | $291.5m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | $57.4m | $46.7m | $54.0m | $36.3m | $331.5m | $99.9m | $105.0m | $203.8m | $291.5m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Additional Financial Items | ||||||||||||
| General and Administrative Expense | $9.3m | $7.7m | $15.3m | $22.6m | $21.9m | $37.3m | $48.1m | $108.1m | — | — | — | |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | $0 | $0 | $0 | $0 | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $14.7m | $22.3m | — | |
| Investment Income, Interest | — | — | — | — | — | — | — | $19.6m | $46.7m | $37.4m | — | |
| Operating Costs and Expenses | — | — | — | — | — | — | — | — | — | $56.1m | — | |
| Operating Expenses | $25.2m | $32.1m | $40.7m | $95.0m | $206.7m | $242.5m | $293.6m | $380.5m | — | $1.3b | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | $0 | $0 | $0 | $0 | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.